BIIB · News · 20260809N

Acquisition / Partnership / Divestiture

BIOGEN INC. · 2026-08-09 · Importance 34 · Surprise 42

Biogen’s acquisition of Apellis contributed to revenue growth in the second quarter of 2026. The transaction expanded Biogen’s portfolio alongside newer therapies in neurology and rare diseases. The reported results suggest the acquired business supported sales growth but did not prevent a significant decline in net income and diluted EPS.

Key facts

• The Apellis acquisition contributed to Biogen Inc.'s growth. source